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Abstract
Background: Recombinant gas vesicles (r-GV) from Halobacterium sp. strain SD109 expressing cassettes with
different SIVsm inserts, have potential utility as an effective antigen display system for immunogen testing in vivo
and for initial epitope assessments in vitro. Previous mouse model studies demonstrated immunization with r-GV
expressing selected exogenous sequences elicited a prolonged immune response. Here we tested segments from
three SIVsm genes (tat, rev, and nef) each surface displayed by r-GV. As with HIV, for SIVsm the proteins encoded
by tat, rev and nef respectively serve critical and diverse functions: effects on efficient viral RNA polymerase II
transcription, regulation of viral gene expression and effects on specific signaling functions through the assembly
of multiprotein complexes. Humoral responses to r-GV
Tat, Rev or Nef1 elicited in vivo, associated changes in selected
cell cytokine production following r-GV internalization, and the capacity of J774A.1 macrophage cells to degrade
these internalized display/delivery particles in vitro were examined.
Results: The in vivo studies involving r-GV immunizations and in vitro studies of r-GV uptake by J774A.1
macrophages demonstrated: (i) tests for antibody isotypes in immunized mice sera showed activation and re-
stimulation of memory B cells, (ii) during long term immune response to the epitopes, primarily the IgG1 isotype
was produced, (iii) in vitro, macrophage degradation of r-GV containing different SIVsm inserts occurred over a
period of days resulting in an inherent slow breakdown and degradation of the SIVsm peptide inserts, (iv) vesicle
specific GvpC, a larger protein, degraded more slowly than the recombinant peptide inserts and (v) in vitro uptake
and degradation of the r-GV populations tested was associated with SIVsm insert specific patterns for cytokines
IL-10, IL-12 and IL-18.
Conclusions: Together these findings provide new information underscoring r-GV potential. They can clearly:
display various exogenous peptides, be intracellularly degraded in vitro over a period of days, affect cell cytokine
levels, and retain their self-adjuvanting capacity irrespective of the specific peptide expressed within the GvpC
protein. These features support the cost effective generation of vaccine components, and provide a simple, self-
adjuvanting system for assessing immune visibility of and specific responses to individual pathogen peptides.
Background
Twenty eight years after the first cases were recognized,
the HIV-1 pandemic continues to grow exponentially
resulting in more than 42 million cases of individuals
living with HIV worldwide. Constant virus replication in
CD4 T lymphocytes initiates progressive immune
defects and finally, after 6 to 10 years, results in
acquired immunodeficiency syndrome (AIDS) and
death. The course of the HIV infection has changed sig-
nificantly with the development of new antiretroviral
regimens that combine inhibitors of reverse transcrip-
tion, virus protein cleavage, or even virus entry. They
reduce viral burden and immune damage caused by
HIV [1] but cannot fully eradicate the virus. Thus, life-
long therapy is expected to transform this otherwise
lethal disease into a chronic, continuously treated infec-
tion by preventing the progression to AIDS. However,
severe drug-related adverse effects and the development
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have not been affordable for the vast majority of
patients worldwide. Because a therapeutic breakthrough
that would soon eradicate HIV or limit side effects
appears unlikely at present, additional therapeutic strate-
gies continue to be relevant to the lasting prevention of
AIDS onset.
A better characterization of the initial host immune
response to HIV-1 infection may help to define protec-
tive immunity to HIV-1. One such strategy might be to
combine antiretroviral treatment with immune
responses to HIV. Some immune control of HIV is evi-
denced by the temporal association of virus reduction
and the emergence of HIV-specific T cells [2], however
in the absence of a pre-infection stimulus, anti-HIV
neutralizing antibodies normally develop too late to play
a key role during natural infections. Findings have sug-
gested that cellular immunity is involved in the initial
control of virus replication in primary HIV-1 infection
and indicate a role for CTL in protective immunity to
HIV-1 in vivo. Importantly, analyses of vaccination stu-
dies in nonhuman primate have indicated that single
viral epitope-specific CTL responses may not be suffi-
cient to block infection with pathogenic SIV [3]. In turn
this suggests that the generation of broader responses
that target multiple viral epitopes may be critical to the
development of effective protection against AIDS. Thus,
a recent alternative approach has involved the use of
multiple HIV antigens and the inclusion of both struc-
tural and regulatory antigens [4]. An indication that this
approach can be more effective has recently been veri-
fied in that in animals, protection from heterologous
SHIV challenge was observed only with immunization
using an aggregated, multiantigen subunit protein vac-
cine that incorporated the structural protein Env and
the regulatory proteins Tat and Nef [5,6]. When indivi-
dually immunized using the same antigens, animals
were not protected. Additionally, studies demonstrated
improved protection from AIDS and CD4
+T-cell deple-
tion in animals immunized with a combination of anti-
gens [7].
Inherently, the microparticulate gas vesicle organelles
produced by Halobacterium sp.N R C - 1h a v en u m e r o u s
characteristics which would be desirable in an antigen
presenting system and thus potentially can have impor-
tance for applications in vaccine development. The orga-
nelles are readily amenable to genetic engineering
techniques that produce gas vesicles expressing on their
surfaces the selected exogenous amino acid sequences,
and the presence of surface borne peptide sequences has
been assessed and verified in vivo [8]. Unlike most
phage or animal virus-derived vaccine components, the
gas vesicle structure does not contain nucleic acid. As a
result, with the proteinaceous gas vesicle system the
potential effects associated with co-introduction of DNA
sequences, inherent in viral or phage based vaccines,
can be completely avoided. The gas vesicles are readily,
rapidly and inexpensively isolated from the bacteria by
lysis in low salt and the isolated nanoparticles are
uniquely stable. Large-scale production of gas vesicles is
simple since these organelles float upon release from the
Halobacteria and thus are easily harvested. Since they
are non-toxic to animals and humans, gas vesicles
should have utility for use as oral as well as parenteral
delivery vehicles.
As initially demonstrated, gas vesicles from a mutant
halophilic archaea SD 109, can be engineered to display
various peptides by insertion of exogenous pathogen
DNA sequences into a site engineered into the gvpC
gene. Thus, expression system plasmids were generated
in which SIVsm gene segments were inserted into site
“d“ engineered within gvpC gene [9]. The plasmid con-
structs were subsequently used to transform the Vac
-
(minus) mutant, Halobacterium NRC-1 strain SD109
and the recombinant gas vesicles harvested and isolated
as described in detail previously [8]. These nanoparticles
were then pre-tested for immunogenicity, antigenicity
and the activation of immunologic memory [9].
I nt h ep r e s e n ts t u d yw ee x a m i n e ds e r af r o md i f f e r e n t
times post-booster and post re-immunization to assess
the antibody isotype elicited in vivo by populations of
gas vesicles (r-GV
Tat, Rev and Nef1) each expressing a
selected SIVsm peptide sequence. Using an in vitro
macrophage cell culture system we then tested for possi-
ble effects of gas vesicle uptake on cytokines produced
by cultured macrophages through quantification of three
(3) key examples: IL-10, IL-12 and IL-18. Finally, given
the known, ultra stable nature of the gas vesicle nano-
particles [10,11] we used in vitro culture in conjunction
with (i) immunofluorescence microscopy and (ii) wes-
tern blot assessments to examine SIVsm and GvpC
molecular weight species as indicators of their degrada-
tion. Thus, the changing intracellular distribution pat-
terns of GvpC positive protein and the incorporated
SIVsm peptide, as well as the molecular weight species
of degradation products were specifically examined.
Results
Immunoglobulins (Ig) are glycoproteins (antibodies)
present in serum and tissue fluids that recognize and
bind their cognate antigen. They constitute the adap-
tive, humoral immune responses, are non invasively
accessible for testing and their utility in vivo is in part
a function of their specific isotype. As a first step in
the present studies, we therefore evaluated our
archived serum to assess antibodies elicited by recom-
binant gas vesicles displaying an SIVsm peptide inserts
(r-GV
Tat, Rev, and Nef1) as a function of immunization
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booster (see Table 1).
Isotyping of immune sera
Based on results from the preliminary sera screenings,
IgG1, IgG2a and IgM were selected for evaluation utiliz-
ing the SouthernBiotech isotyping kit as described in
the methods. The assay results are presented graphically
in Figure 1 which plots the isotypes detected at the opti-
mum antigen specific antibody dilution. This antigen
specific approach allowed determining the predominant
isotype elicited and present at different times post-
immunizaton or booster.
As the histograms in panels of Figure 1 show, with
two exceptions (R3 and N3), IgG1 is the predominant
isotype at 2, 8 and 17 weeks post second booster. Seven-
teen weeks later, the mice were re-immunized using ali-
quots of the same r-GV preparations and sera collected
at 10 days and again at 43 weeks post re-immunization.
The isotyping results for samples from these time
points, shown in Figure 1, confirm that for all the mice
tested, IgG1 remains the predominant isotype including
the assessments of sera drawn at 43 weeks post re-
immunization. For sera of all animals, at the optimum
antigen specific dilution, IgG1 remained the predomi-
nant isotype and its signal was greater than that of the
10 day post re-immunization samples indicating the spe-
cific antibody responses continued to develop over time.
Determination of key cytokines elicited from J774A.1
macrophage cells
In recent years the expression “cytokine network” has
become commonly accepted in biomedical research and
that network now includes several hundred members.
Using our in vitro monolayer system this study assessed
the levels of three key cytokines as a function of r-GV
uptake by macrophage cell monolayers. The studies had
two aims: first to evaluate whether uptake of gas vesicle
particles by these monolayer cells could influence the
detectible levels of cytokines in the surrounding media
and second, to determine whether there were differential
cytokine levels as a correlate of the specific SIVsm pep-
tide expressed by the r-GVs applied to the individual
monolayer cells. Positive findings would add to a profile
that characterizes peptide specific effects in vitro as well
as to the potential utility of this nanoparticle delivery
system.
There are known interactive influences for each cyto-
kine and macrophages normally produce IL-10, IL-12
and, IL-18, among others. IL-12 and IL-18 have impor-
tant roles in inducing TH1 responses while IL-10 can
antagonize the generation of TH1 subset of helper T
cells and enhance proliferation of B cells. Further,
macrophages are widely distributed in mammalian tis-
sues and fluids. Therefore assessment utilized mono-
layers of J774A.1 murine macrophages and the protocols
for in vitro r-GV application, followed by quantification
of cytokines in the culture media as described in the
methods section. To test whether there might be r-GV
insert specific differences, cell monolayers were incu-
bated for 2.5-3 h with wt-GV (NRC-1) a control, or
with the different r-GV
Tat, Rev or Nef1. At the times speci-
fied after GV removal and rinsing, aliquots of culture
media were harvested and stored at -20°C until assessed
for their content of the selected cytokines. Cytokine
quantifications used point to point curves generated by
assay of the individual purified cytokines provided in the
cytokine kits and the calculation methods recommended
by the kit manufacturer. Concentrations of the three dif-
ferent cytokines were assayed in media of cultured cells
receiving no gas vesicles, media from duplicate cultures
treated with one of the different SIVsm insert contain-
ing r-GV populations, or with the insert negative wild
type control from NRC-1. Table 2 presents these results
which are snapshots in time of individual cytokine levels
with the elevated levels shown in bold and shows there
are notable differences in concentrations, and these vary
as a function of the SIVsm insert and also the time post
application. Thus for r-GV
Tat or Revsamples, concentra-
tions of IL-10 and IL-12 were maximal at 12 h post
application (185.311 and 147.218 pg/ml respectively),
then declined. For samples of r-GV
Nef1,t h ep e a kI L - 1 0
concentration was much higher and occurred at 24 h
(537.38 pg/ml); although lower in the 48 h samples, it
was still elevated (168.622 pg/ml). For IL-12, maximal
concentration again occurred early at 12 h for r-GV
Tat
treated cultures (52.680 pg/ml), then decreased to the
level of the insert negative NRC-1 in the 48 h sample.
In contrast, for r-GV
Rev or Nef1 media, increased pg/ml
Table 1 Immunization regime of the BALB/c mice using
r-GV
Time points C, Tat, Rev, Nef1
DOB 10/03/03
Prebleed 01/08/04
1
st immunization 01/08/04
2 weeks/immunization 01/22/04
4 weeks/immunization + 1
st boost 02/05/04
4 weeks/1
st boost + 2
nd boost 03/04/04
2 weeks/2
nd boost 03/18/04
4 weeks/2
nd boost 04/01/04
8 weeks/2
nd boost 04/29/04
12 weeks/2
nd boost 05/20/04
17 weeks/2
nd boost + re-immunization 06/24/04
10 days/re-immunization 07/04/04
Final bleed 04/15/05
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Page 3 of 16Figure 1 Predominant Isotype Identification. Isotypes of sera collected at different post booster or re-immunization times were determined
using sera pre-adsorbed with wt-gas vesicles and assessed using isolated recombinant GV as the SIVsm antigen source. As detailed in the methods,
sera diluted to the pre-established optimum were incubated in the r-GV pre-coated wells. Following rinses and incubation with pre-conjugated
isotype specific antibody, isotype specific binding was detected by addition of pNPP substrate and absorbances quantified at 405 nm.
Table 2 Assessment of the cytokine concentrations (pg/ml) at 12, 24 and 48 hours post gas vesicle addition
IL-10 (pg/ml) IL-12 (pg/ml) IL-18 (pg/ml)
12 h 24 h 48 h 12 h 24 h 48 h 12 h 24 h 48 h
Media
† 29.791 32.794 31.677 7.276 10.908 13 17.037 15.163 10.606
NRC-1
‡ 27.037 28.712 28.774 11.795 9.643 13.086 72.51 76.747 78.739
Tat 185.311 28.476 31.404 52.680 14.048 13.653 85.332 115.166 106.121
Rev 147.218 67.513 37.792 9.959 10.693 19.830 99.325 56.274 55.549
Nef1 31.739 537.384 168.622 8.675 6.498 54.730 68.855 68.935 72.456
† As detailed in the methods, macrophage monolayers received media only.
‡ Control wells received the wild type gas vesicles NRC-1.
Sremac and Stuart BMC Biotechnology 2010, 10:54
http://www.biomedcentral.com/1472-6750/10/54
Page 4 of 16were detected only in the 48 h samples with Nef1 exhi-
biting the higher concentration (54.730 pg/ml). Finally
for IL-18, samples from r-GV
Tat or Rev treated cultures,
the 12 h samples displayed some elevation in concentra-
tion (85.332 and 99.325 pg/ml) that somewhat exceeds
the elevated levels detected in samples from the cultures
exposed to the insert negative control, gas vesicles from
NRC-1 (72.51 pg/ml). At later times, IL-18 levels were
additionally elevated by r-GV
Tat, with the higher levels
occurring respectively at 24 and 48 h. (115.166 and
106.121 pg/ml). In r-GV
Rev treated samples, the 12 h
time displayed elevated IL-18 (99.325 pg/ml) but this
decreased to ~half that concentration in the 24 h and
48 h post-addition samples. In contrast, at the different
times tested, monolayers treated with r-GV
Nef1 displayed
no significant increases in IL-18 concentrations (68.855-
72.456 pg/ml). In fact the levels were marginally lower
than those from samples from insert negative NRC-1
cultures (72.51-78.739 pg/ml). Therefore these assays
indicate that unlike assays for r-GV
Tat and Rev,r - G V
Nef1
elicited no significant inserts p e c i f i ci n c r e a s ei nI L - 1 8
concentrations.
Although these data are “snapshots”, nevertheless they
indicate there are quantifiable, SIVsm insert specific dif-
ferences and time dependent effects on cytokines pro-
duced by J774A.1 cell following the application and
internalization of r-GV
Tat, Rev or Nef1. Thus in the context
of an antigen delivery vehicle, there clearly is a detectible,
insert specific impact on cytokine production by recipient
monolayers. These results therefore add to an overall pic-
ture characterizing the immunogen as delivered via the
r-GV system. They also suggest r-GVs could potentially
be further designed for a co-delivery specifically aimed at
simultaneously affecting cytokine levels.
Intracellular fate of gas vesicles
At 50-1000 nm, individual gas vesicle nanoparticles are
below the limit of light microscope resolution [9] but
clusters of them, and of their breakdown products are
detectible by immunostaining. Gas vesicles are remark-
ably stable particles [10-12] and thus may inherently
result in a slow release of the incorporated peptide
sequences. Therefore r-GV, their fate and susceptibility
to timely degradation constitute critical parameters in
context of in vivo applications.
Immuno-microscopy assessment of r-GV intracellular fate
Studies directed at examining the post-phagocytic fate of
the recombinant nanoparticles used specific antibody
probes to detect the SIVsm encoded peptides and the
GvpC protein per se. This protein contains the insert
and specifically identifies gas vesicle particles. Using the
protocols specified in the methods, the J774A.1 macro-
phage cell line monolayers were prepared and incubated
with r-GV then fixed as described at the different, speci-
fied times and stored at -20°C for subsequent assess-
ments. Immunostaining with appropriate primary
antibody allows immunofluorescent detection of r-GV
delivered SIVsm peptides -Tat, Rev or Nef1 and sepa-
rately, of the gas vesicle protein, GvpC. The initial distri-
bution of r-GV material following internalization by
monolayer cells is shown by the low magnification
(400×) micrograph in Figure 2. It provides an overview
of representative control and r-GV
Tat, Rev and Nef1 treated
monolayers. These samples were harvested at 12 h post
r-GV treatment and subsequently immunostained with
the anti-SHIV monkey plasma which identifies the
SIVsm peptide. Use of this plasma verifies that antibo-
dies elicited during in vivo infection with live, native
SHIV recognizes the r-GV
SIVsm peptides synthesized by
the halobacteria as if they were native SIV protein. The
monolayer in panel A of Figure 2 is a control to test for
non specific antibody binding. It was not incubated with
gas vesicle preparation and clearly the monolayer exhi-
bits only a background fluorescence signal. In contrast,
monolayers treated with r-GV show numerous cell
Figure 2 Demonstration of gas vesicles phagocytosis by J774A.1 monolayer cells. Gas vesicle preparations were added to monolayer cells
as described, subsequently removed and the monolayers rinsed with fresh media, then maintained in culture. These representative 12 h post
treatment micrographs of immunostained samples demonstrate that appropriate antibody detects each of the SIV encoded peptides in
numerous cells of the r-GV treated monolayers. Control monolayers - A, received media only. Experimental monolayers received media
containing purified gas vesicle preparations expressing Tat - B, Rev - C or Nef1 - D. Original magnification 400×.
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treated monolayers (Panel B and C). For the larger Nef1
insert (Panel D), there also are cells that appear to
“glow”. This fluorescence labelling shows the more
extensive binding of anti-SHIV primary antibody to the
larger Nef1 peptide contained in r-GV
Nef1 particles.
A second, critical characteristic is the susceptibility of
the r-GV delivery vehicle to intracellular degradation that
releases the SIV inserts for processing by the cell. The
fate of the SIVsm insert was followed in immunostained
samples harvested over a period of 12-120 h and repre-
sentative 1,000 × images of immounostain results are
presented in Figure 3. As would be anticipated, these
show that the SIVsm specific staining appears to become
more diffusely distributed in the cells both as a function
of the elapsed time, and the specific insert. At 12 h, SHIV
positive particles (r-GV
Tat, Rev or Nef1) appear to be asso-
ciated with the monolayer cells, internalized by them,
often as a cluster (ex. Rev, upper right) or internalized to
produce a somewhat more diffuse green fluorescence
Figure 3 Intracellular degradation of SIV specific peptides from gas vesicle treated monolayers. Immunostaining of r-GV
Tat. Rev or Nef1
treated monolayers with anti-SHIV antisera demonstrates the time dependent disappearance of these epitopes from the macrophages. Note that
for all three, the epitope specific immunostaining diminishes over time: 24-120 h post application. Additionally, the level of fluorescence
detected is consistent with the SIV insert size. For the samples harvested at 48 h post addition, the larger Nef1 insert, expressed by r-GV
Nef1
appears more intensely stained than the inserts for r-GV
Tat or r-GV
Rev. Original magnification 1000 ×.
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Page 6 of 16(ex. Nef1). By 48 h the bright punctuate staining of Rev
and Tat has diminished, becoming more diffuse, and
these cells do not ‘glow’. However for Nef1, the largest of
the SIVsm encoded insert tested, distinct regions of
‘glow’ remain, likely because the degradation of this lar-
ger SIV insert remains less complete. However by 96 h,
the immunostaining for Nef1 also has become more gen-
eralized. Interestingly, for the sample receiving r-GV
Rev,
nuclear regions of the cells immunostain quite brightly
and in the 120 h Rev sample, this apparent nuclear asso-
ciation is clearly evident. Though not as distinct, a similar
nuclear association occurs with the Tat insert. In con-
trast, the r-GV
Nef1 treated sample does not exhibit this
distribution. Additionally, at the 120 h time, the diffuse,
lightly stained areas detected in the cytoplasm of the
r-GV
Nef1 sample appear similar to the cytoplasmic distri-
butions detectible in the 48 h r-GV
Tat sample. This later
appearance in the r-GV
Nef1 treated monolayer might be a
function of slower breakdown of this larger expressed
peptide. As expected, for each of the three different r-GV
populations, the immunostaining of the incorporated
SIVsm derived inserts is consistent with ongoing r-GV
breakdown of the individual clusters and concomitant
disappearance of detectible, brightly fluorescent particle
clusters.
Other companion monolayers were similarly rinsed,
fixed, then immunostained using anti-GvpC specific
antibody to detect the larger, gas vesicle specific “C”
protein and Figure 4 presents a temporal series of repre-
sentative images from 12-120 h post r-GV application.
Relative to the SIVsm inserts, GvpC is a large protein
and like gas vesicle proteins in general, is resistant to
dissociation/degradation [10,11]. Immunostaining to
identify GvpC initially gives rise to cells exhibiting an
overall glow that becomes significantly diminished by
the 96 h time point and this would be consistent with a
slow degradation of GvpC. However, positive but muted
and somewhat diffuse punctuate immunostaining
remains at the 120 h time and can support suggesting
that full degradation of GvpC remains incomplete at
this time.
In the context of a display/delivery particle, it is
important that cells can both internalize the r-GVs, and
successfully degrade them, allowing release of the patho-
gen specific insert they carry. The observed level and
distribution of immuno-reactive GvpC material in
monolayers at the 120 h time is fully consistent with
ongoing particle degradation. Additionally, the decreas-
ing brightness of the immunostaining supports suggest-
ing the degradation time frame for and perturbation by
GvpC will extend beyond the time required for the
degradation of SIVsm inserts.
Western blot assessments verify intracellular breakdown
of SIVsm and GvpC components of r-GV
Ultimately, the processing and removal of immunogens
and their carriers is a significant factor for in vivo appli-
cations. Therefore the fate of the GvpC and SIVsm
components detected by immuno fluorescence micro-
scopy during the late stages post r-GV application were
examined further. Based on the patterns observed in
these preparations, samples from the 96 h and 120 h
were additionally assessed to verify protein breakdown.
Other J774A.1 monolayers were incubated with the gas
vesicle preparations under the same conditions, then
rinsed and harvested. These samples were assessed by
preparing cell lysates and separating the protein species
using 4-12% SDS-PAGE gradient gels as detailed in the
methods.
In acrylamide gels, pure intact GvpC protein behaves
anomalously relative to its actual molecular weight,
migrating as a species of ~60 kDa [9]. Following separa-
tion using SDS-PAGE, and transfer to PVDF membrane,
GvpC peptides and the expressed SIVsm insert were
detected using the same anti-GvpC antibody stock and
anti-SHIVsm monkey plasma utilized for the mono-
layers in immunostaining studies; companion halves of
blot membranes were probed with the respective speci-
fic antibodies. Figure 5 presents typical Western blots of
samples from the 96 h (upper blot pair) and 120 h
(lower blot pair) time points, probed respectively with
anti-GvpC antibody or anti-SHIVsm plasma. GvpC is
synthesized by the recombinant bacteria and an integral,
surface displayed component of these gas vesicles. The
observed immunostained bands of differing kDa are a
reflection of the molecular weights of GvpC breakdown
products; other associated degradation resistant gas vesi-
cle structural proteins also would be expected and if still
integrated with GvpC, would affect its migration in gels
[9]. The presence of multiple protein bands identified
for r-GV samples and for the SHIV peptide is consistent
with the immunostain microscopic observations which
also suggested r-GV break down is a process that con-
tinues over a period of days. The membrane half probed
with anti-GvpC antibody specifically identifies GvpC
protein and peptides. It detected a number of bands at a
variety of molecular weights, rather than the single
~60 kDa band that would characterize intact GvpC pro-
tein. The majority of bands in blots of the 96, and 120 h
samples appear at < ~40 kDa with heavily stained bands
detected at ~20 kDa and at somewhat at less than
14 kDa. The immunostain of these bands is notably
stronger at the 120 h time, indicating GvpC breakdown
is continuing and gives rise to these species, but clearly
is still incomplete. Importantly, some bands may exhibit
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tance to the standard protein dissociation protocols
[10,11].
Slow disassembly and intracellular degradation would
not be unexpected for gas vesicle proteins and likely
perturbation of cells by partially degraded GvpC frag-
ments would continue for an additional, but finite per-
iod of time. In contrast, the companion SIVsm inserts
of Rev, Tat and Nef1 remain detectible but for the 96 h
sample, the peptides immunostain lightly with the anti-
SHIV antibody. Notably the inserts are an integral part
of GvpC and like other GV proteins, GvpC is resistant
to degradation. Multiple but light staining bands
detected with the anti SHIV antibody would therefore
be expected. At 120 h, the bands recognized by anti-
SHIV antibody are minimally in evidence. No immunor-
eactive high molecular weight bands are obvious and
the molecular weight species of ~6 kDa or less now are
Figure 4 Intracellular degradation of GvpC specific protein of gas vesicles. Companion J774A.1 monolayers were prepared under
conditions identical to those used for samples in figure 3 and similarly examined microscopically. This panel, immunostained with rabbit anti-
GvpC antibody, demonstrates this gas vesicle specific protein also disappears over time. The quantities of GvpC protein remaining at the 120 h
time appear greater than that observed for the SIVsm inserts. This would be consistent with the larger size of this protein and likely would
support continued perturbation of cells following particle phagocytosis. Original magnification 1000 ×.
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Page 8 of 16Figure 5 Differential breakdown of GvpC and SIVsm components demonstrated by western blot. Monolayer samples were harvested at
different times post application of gas vesicles, then mixed with 5× SDS-PAGE sample buffer and subsequently assessed through western blot
detection of GvpC or SIVsm material as described in the methods. These representative western blots demonstrate that at both the 96 and
120 h times examined, strong bands detecting GvpC are evident. For the much smaller SIV component of the same gas vesicles, numerous
weak bands were evident at the 96 h time but by 120 h, the bands detected were very light and evident only at molecular weights ≤ 14 kDa.
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integration into the original GvpC framework protein,
the SIVsm inserts are accessible to degradative proces-
sing. Therefore these foreign proteins ultimately should
be cleared by cells.
Discussion
The studies presented above were designed to further
assess practical aspects of the recombinant gas vesicle
display/delivery system through in vitro and in vivo stu-
dies. As a self-adjuvanting, highly stable component
[13], r-GV have significant potential as an alternative
delivery system and thus the studies reported were
designed to provide additional characterizations. The
SIV fragments tested were selected because they are key
immunogens examined as relevant gene products in
other published research [14,15] Those studies had
shown toxoids of Tat or Tat and Rev, or delivery of
aggregated multiantigens, provided some disease
attenuation [5,6] whereas use of Tat alone for example,
provided only temporary infection containment. This
was interpreted to mean a single antigen might not be
adequate to provide full and/or long term protection
[14-19]. Our recombinant system inherently supports
the expression and delivery of various epitopes [8,9,13]
and could be readily adapted if important, new peptides
were identified. Thus combinations of r-GV particles
could be easily created for use in vivo and this would
provide exposure to multiple antigen fragments and
thereby elicit a variety of peptide specific antibodies.
Different isotypes bind to cell surface expressed Fc
receptors in vivo and the resulting receptor derived cell
stimulation then will initiate a cascade of effects that
can impact the local milieu, and ultimately cell func-
tions. Utilizing the optimum antigen specific dilution of
each antibody sample as determined by pre-titration
using the specific Tat, Rev, and Nef1 antigens, the pre-
sent studies identified the isotype(s) elicited by r-GV
immunizations. These analyses showed IgG (primarily
IgG1 with some instances of minimal IgG2a) was the
predominant immunoglobulin species (Figure 1).
Although for the R3 and N3 groups, IgM was predomi-
nant at 10 days, at 43 weeks, in the absence of any sub-
sequent booster, IgG1 was the dominant isotype in all
samples.
This can be relevant in vivo since antibody isotypes
impact downstream events through antibody binding to
cell displayed Fc receptors [20]. Additionally, the contin-
ued presence of antigen specific mouse antibodies 301
days (43 weeks) after the final re-immunization, is
potentially an important feature for an immunizing
agent and likely to be relevant in terms of practical uti-
lity. The isotyping data also inherently demonstrated
that the peptides encoded by the expressed small DNA
inserts (tat-150 bp and. rev-243 bp), are immunogenic
and as shown in Figure 3, relative to the expressed nef1
encoded insert (642 bp) appear to be degraded more
slowly than their actual size would predict. This finding
may reflect the central location of these encoded small
peptide inserts, 50 and 81 amino acids respectively,
within the GvpC protein. At that site they may be less
readily accessible to the intracellular degradation pro-
cesses. Nevertheless they are immune visible and evoke
specific antibody responses.
Gas vesicles are particulate moieties and when phago-
cytosed can impact various cell functions, including
cytokine production. In turn, both individually and in
combination, cytokine levels significantly affect the nat-
ure and level of immune responses and response polari-
zation in terms of antibody (Th2), and cell mediated
immunity (Th1) [21,22]. In vivo, cytokines impact
immune related processes and certainly specific roles for
different cytokines have been identified and extensively
investigated. Studies of HIV for example, have demon-
strated cytokine correlations with protection from infec-
tion, prediction of disease progression and impact on
immune response polarization [23-26]. Based on the
potential for an insert specific effect, the present in vitro
studies assessed the r-GV immunogens for their possible
impact on selected cytokines, quantified by testing the
media of monolayers treated with r-GV
Tat.Rev and Nef1,
vs. wt-GV, or left untreated. Although the SIV specific
peptide inserts constitute a very small segment in the
recombinant GvpC protein, nevertheless in vitro studies
showed there were detectible, insert specific differences
in the cytokine patterns and the temporal profiles of
their changing concentrations (Table 2). Given the
known effects of cytokines IL-18, IL-10 and IL-12, and
data in the literature relating to Tat, Ref and Nef1, the
present findings show that despite the preponderance of
GvpC specific protein, even very small segments of
these pathogen proteins could play specific and signifi-
cant roles in vivo by influencing the local milieu [27-29].
Although in vitro effects can not fully reflect in vivo
process or responses, they nevertheless can indicate the
potential to exert an effect. Analogous consequences in
vivo could alter the local milieu and thereby alter the
Th1/Th2 responses equation. In turn, this might affect
vaccine efficacy and certainly adds to a characterization
of this immunization vehicle. Thus similar examinations
would be relevant in the broader context of vaccine
development, and of characterizing pathogen impact on
tissues or systems. Known examples are inhibitory
effects of IL-10 on HIV-1 production in monocytes/
macrophages resulting from IL-10 stimulated inhibition
of cytokine syntheses e.g. tumor necrosis factor alpha
(TNF-a) and IL-6. In the context of HIV-1, this altera-
tion can up-regulate pathogen expression in the infected
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described IL-10 inhibitory effects on cytokine synthesis
[31-33], and on pathogen (HIV) replication in mono-
cytes [30,34].
The inherent physical stability of the gas vesicle struc-
ture, along with its resistance to chemical dissociation
or proteolytic cleavage [12,35,36] and its particulate
structure, likely play a role in the natural slow release of
the incorporated epitope containing fusion proteins and
could enhance stimulation of the immune system. Ulti-
mately however, the full degradation of the particulate
r-GV immunogen is important. Their long term pre-
sence potentially could elicit chronic, local inflammatory
responses that can characterize degradation resistant
particles. The in vitro immunostaining and the Western
blot findings presented here were aimed at assessing
intracellular GV breakdown. The results indicate that
degradation of these naturally stable immunogenic parti-
cles does occur and demonstrates the sizes of degrada-
tion products. In this context, it is noteworthy that even
long term, oral ingestion of gas vesicles on a regular
basis [37] has provided no evidence that gas vesicles
exhibit any detectible short or long term toxicity. Thus
per-oral usage of r-GV also could be an option.
Micrographs from the immunofluorescence staining
allow the tracking of r-GV intracellular fate after the
application to J774A.1 cells monolayers in vitro.T h e s e
studies demonstrated that as expected, r-GV are phago-
cytosed. Microscope focusing indicated r-GV associated
with and/or were within J774A.1 macrophages at 12 h
post application and clearly internalized at later times
(see Figures 2 and 3). Results from the subsequent
immunostain monitoring of both the gas vesicle protein
GvpC, and the SIV specific inserts confirmed their slow,
progressive disappearance over time. An intracellular
accumulation/coalescence of individually internalized
r-GV particles clearly takes place and is evident in the
micrographs of 12 h post application monolayers. Addi-
tionally, samples from various times (12-120 h) follow-
ing removal and rinsing off of the applied r-GV
Tat, Rev or
Nef1 were immunostained using either anti- SHIV or
anti-GvpC antibody (Figure 3 and 4) and examined.
These clearly show a decrease in detectible immunos-
tained material during this time course. The results
from this group of studies therefore provides critical
information in terms of potential r-GV utility as a deliv-
ery vehicle since it indicates that in vivo there should be
an ongoing but distinctly finite host cell perturbation
following cellular uptake. This likely would impact
immune stimulation, potentially by processes including
the stimulation of cytokine production detected and
quantified above. Importantly the present studies track-
ing degradation indicated that over time in vitro,t h e
recombinant particles did undergo degradation in the
individual cells. This was evidenced by the immunomi-
croscopy data for samples (Figures 3 and 4) and was
verified in more detail by the Western blot assessments
which tested lysates of r-GV treated monolayer at 96
and 120 h post r-GV applications (Figure 5).
Since recombinant inserts are expressed in gas vesicle
protein ‘C’, studies assessed breakdown of this protein
species and also of the specific expressed SIVsm inserts.
In SDS-PAGE gels isolated, intact GvpC would appear
as a single, ~60 kDa protein species [9]. The Western
blot analysis using anti-GvpC showed clearly that wt-
GV and the r-GV
Tat, Rev and Nef1 recombinants all exhib-
ited multiple molecular weight species at both 96 and
the 120 h times after application to monolayer cells.
This is the predicted result when proteins that become
internalized are broken down and is consistent with the
immunostaining detected in Figures 3 and 4. It also
would be expected that the band patterns in SDS-PAGE
gels, and the density of Western blot immunostained
bands would change as a function of time and this is
the case (Figure 5, left hand panels). Thus, by 120 h,
there are crisp GvpC positive bands of lower molecular
weight species (ex. somewhat greater than 18 kDa and
less than 14 kDa), as well as higher molecular weight
species which are now more lightly stained by the anti-
GvpC antibody. All of these bands are reactive with the
anti-GvpC antibody, and since in SDS-PAGE gels, GvpC
that is un-degraded behaves as a 60 kDa moiety [9];
these clearly are degradation products from the GvpC
protein. They exhibit discrete, decreasing molecular
weights consistent with degradation that is ongoing over
time. Similarly the companion Western blots probed
with anti-SHIV specific antibody demonstrated break-
down of the SIVsm derived inserts and showed the dis-
appearance of bands over time (Figure 5, right hand
upper and lower panels). In addition to the detailed
findings, the results overall support the conclusion that
intracellular r-GV are susceptible to degradation and
therefore can be cleared from cells that may phagocy-
tose them. Furthermore, unlike the effects on cytokine
concentrations, inserts in r-GV
Tat, Rev or Nef1 do not
appear to significantly alter the r-GV time course of
degradation in an insert dependant way.
Conclusions
The studies presented here provide an initial examina-
tion of recombinant gas vesicles (r-GV) in terms of pre-
dominant antibody isotype elicited in vivo,p a r t i c l e
impact on selected cytokines elicited following uptake
by monolayer cells in vitro and r-GV internalization and
intracellular degradation during in vitro culture. The
murine immunizations showed that despite the relatively
small size of the expressed recombinant insert, like
other haptens SIVsm derived inserts incorporated into
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clearly visible and can initiate immune responses. Addi-
tionally, the level of murine humoral responses observed
likely would reflect effects from gas vesicle elicited cyto-
kines and the natural slow but progressive release of
antigen over time.
The complexity, functions and detailed interactions of
cytokine and their network are well outside the scope of
these studies; however in vitro effects of cell perturba-
tion by gas vesicles and their SIV derived inserts could
establish a profile of cell responses relevant in the con-
text of an antigen delivery system. Screenings for possi-
ble insert specific effects examined IL-10, IL-12 and IL-
18 which have been implicated as protective during
infection by intracellular pathogens [21,38-41]. There-
fore studies quantified these three to obtain a profile of
insert specific effects. The assay results showed that
despite the small size of the SIV inserts, changes are
evoked that differ quantitatively and temporally depend-
ing on the recombinant r-GV applied. Thus each had
unique, signature effects when phagocytosed by cells
and therefore would exert a different but characteristic
impact when used as an immunogen. These findings
indicate that cytokine analys e st h a tt a r g e t e de x a m i n i n g
the effect of individual peptide immunizing agents could
be highly relevant as an additional parameter that aids
in characterizing the epitope(s) of those agents.
The in vitro time course examining r-GV uptake and
fate used immunostaining with rabbit anti-GvpC and
monkey anti-SHIV antibodies to detect and assess a
time course for intracellular breakdown of phagocytosed
organelles. The distribution of fluorescence labelling
demonstrated the progressive loss over time of protein
specific immunostaining. As a larger protein species
there was an inherently slower clearance of the gas vesi-
cle protein, GvpC vs. the viral inserts which are small
peptides. In terms of in vivo host immune responses,
slower degradation would extend the period of cell per-
turbation. In turn this could impact cells and their pro-
cesses - antibody production, specific antibody isotype(s)
generated, and the specific cytokine profiles elicited.
The complexity, functions and detailed interactions of
cytokines and their network were outside the scope of
these studies but the in vitro effects of cell perturbation
by gas vesicles indicated screening for possible insert
specific effects on IL-10, IL-12 and IL-18 would be a
highly relevant parameter in defining the SIV epitopes
of interest here [21,37-40]. These cytokines therefore
were quantified to obtain a profile of insert specific
effects. The results showed r-GV
Tat, Rev and Nef1 each
evoke changes that are quantitatively and temporally dif-
ferent. Therefore each likely would have unique, signa-
ture effects when phagocytosed by cells and thus would
exert different but characteristic perturbations. The
impact of Th1/Th2 balance on immune responses to
antigen perturbation is crucial: Th1 responses supports
inflammation and T and macrophage cell activation,
while Th2 actives primarily B cells, resulting in antigen
specific antibody. The cytokine quantifications were car-
ried out as described using the in vitro cell culture sys-
tem and there were notable temporal and quantitative
differences. Clearly responses generated in vivo vs. in
vitro can differ significantly as the former is a far more
complex environment. Thus, in the absence of in vivo
data there is no valid basis to speculate about the effect
of this mode of antigen presentation in vivo.H o w e v e r ,
the findings suggest that cytokine analyses to establish
the effect(s) of individual peptide immunizing agents
delivered by r-GV could be generally useful as an addi-
tional parameter characterizing epitopes that are being
selected for vaccine usage.
Cell uptake of r-GV
Tat, Rev or Nef1 results in character-
istic; insert specific changes in the three cytokines
assessed. The precise mechanisms of immune response
regulation in vivo are highly complex. However, for par-
ticulate antigens, such as those tested here, internaliza-
tion and degradation by dendritic cells or macrophages
would be a critical initial step in the process. The in
vitro findings indicate that the highly stable gas vesicle
particle is readily and rapidly internalized by macro-
phages such as the J774A.1 cell line used here. The in
vitro time course demonstrating the intracellular break-
down used rabbit anti-GvpC and monkey anti-SHIV
antibodies. It demonstrated the progressive loss of pro-
tein specific immunostaining over time and as expected,
the larger Nef1 insert was degraded more slowly than
the Tat and Rev components. The later stages of this
process also were examined by Western blot. As
expected, these clearly showed the array of molecular
weight species formed during intracellular breakdown. It
demonstrated the progression of changes and verified
that at the 120 h time, breakdown remained incomplete
and thus would continue to perturb the cell. As a larger
protein species the inherent slower clearance GvpC vs.
the viral insert likely reflects primarily the larger size of
the GvpC component. However, in terms of host
immune responses, GvpC’s slower disappearance, an
indicator of degradation, likely results in an extended
period of cell perturbation. In vivo perturbation can
impact processes such as stimulation of antibody pro-
duction, the specific antibody isotype(s) that ultimately
is formed, and the changing profile of cytokines
produced.
Finally, the results overall support the conclusion that
although the SIV inserts tested here differ in amino acid
sequences, expressed peptide size and in vivo function
during infection, both the Western blot data, and the
fluorescent microscopy studies show the inserts do not
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Interestingly, intact Rev and also Tat proteins would
normally track into the nucleus during in vivo infection
by HIV [42,43]. The immunostained 120 h micrographs,
demonstrate that numerous cell nuclei specifically
reacted with the anti-SHIV antibody, some even exhibit-
ing a green “glow”. Thus data from the r-GV
SIV treated
monolayer cultures suggest that in this in vitro system,
the Rev peptides in particular, but also Tat can enter
the nuclear compartment of J774A cells. Potentially
therefore, an inherent characteristic, amino acid
sequence remains fully functional when expressed in
GvpC-SIV protein chimeras and effectively targets the
nucleus.
Methods
Isotype determinations
Isotype identification used sera elicited by initial immu-
nizations with r-GV followed at intervals by boosters of
50 μg r-GV/mouse using the regimen presented in
Table 1 and assessed for anti-r-GV titer by ELISA [8].
These sera, designated based on the portions of the viral
gene segment they expressed (e.g. tat-150 bp, rev-243
bp and nef1- 6 4 2b p )w e r es t o r e da t4 ° Ca n df u r t h e r
examined here to determine the predominant isotype of
t h ea n t i b o d yt h a ts p e c i f i c a lly recognizes the SIVsm-
sequences expressed by the different r-GV populations.
Antibody to gas vesicle proteins present in anti-SIVsm-
Tat, -Rev, or -Nef1 mouse sera was adsorbed by sequen-
tial incubation with wild type gas vesicles (wt-GV) and
the absorbed sera then titered using standard ELISA
methods and the appropriate recombinant gas vesicle
preparations (r-GV
Tat, Rev, or Nef1)a st h ea n t i g e n[ 8 ] .
That optimum antibody dilution then was isotyped
using reagents from SouthernBiotech (1070-04, 1080-04,
1021-04; SouthernBiotech, Birmingham, AL) which pro-
vide the necessary isotype specific antibody. The manu-
facturer’s protocol was followed and except as noted,
incubation was carried out for 1 hour (h) at room tem-
perature (RT). Gas vesicles function as flotation devices
for Halobacteria and were routinely collapsed (deflated)
by brief centrifugation using a microfuge as described
previously [8]. Collapsed gas vesicles will settle onto and
associate with wells of ELISA plates, and likewise will
associate with monolayer cell surfaces allowing subse-
q u e n tp h a g o c y t i cu p t a k eb yt h e s em a c r o p h a g e s .B r i e f l y ,
ELISA wells were coated with the appropriate collapsed
gas vesicles diluted to 1 μg/100 μli nP B S ,a n ds u b s e -
quently blocked with 1% BSA/PBS, then incubated with
mouse antisera appropriately diluted in 0.1% BSA/PBS.
Control wells in the plates were also coated using the
same collapsed gas vesicle preparations but received
0.1% BSA/PBS containing no primary antibody. After
rinsing 4×, each well received 100 μl of a 1:1,000
dilution of pre-conjugated isotype specific antibody and
plates were again incubated for 1 h at RT. Wells were
then rinsed 5× with 0.1% BSA/PBS, and incubated at
37°C with 100 μl of pNPP substrate solution. Absor-
bance readings at 405 nm were taken at 10, 20, 30 and
60 min, using a VersaMax ELISA Reader (Molecular
Devices, Palo Alto, CA).
Cell Culture and Application of Isolated Gas Vesicles
Murine macrophage J774A.1 cells were grown to 75-80%
confluence on 12-mm glass cover slips (Fisher Scientific,
Pittsburg, PA) in 12 well plates (BD Falcon, Franklin
Lakes, NJ) using the Richter’s Improved Minimum Essen-
tial Medium with Insulin (IMEMZO, Irvine Scientific,
Santa Ana, CA) containing 10% Fetal Bovine Serum
(FBS, Atlanta Biologicals, Norcross, GA) at 37°C and 5%
CO2. At ~ 80% confluence the media was removed and
the cells washed 3× with fresh IMEMZO, 500 μl/well.
For cultures used in the cytokine assays wild type gas
vesicles (from Halobacterium NRC-1) as well as recombi-
nant gas vesicles, previously purified, dialyzed and col-
lapsed by microcentrifugation [8] were diluted in sterile
serum free media (SFM) (QBSF®55, Sigma-Aldrich, Inc.,
S a i n tL o u i s ,M O ;Q 3 8 7 8 )a n d4 0 0μl/well sterilely added
to the appropriate wells to give a final concentration of
500 μg/ml. Wells serving as controls for the effect on
cytokine levels of in vitro cell culturing per se, received
SFM containing NRC-1 gas vesicles. For studies of gas
vesicle degradation, SFM was used throughout. These
monolayers also received 400 μl/well of the 500 μg/ml
isolated gas vesicle stock, delivered in media. For the
degradation studies the control wells received SFM with-
out gas vesicles and for both studies, plates were incu-
bated at 37°C with 5% CO2 for 2.5-3 h. After incubation,
the recombinant gas vesicles containing media was
removed from the wells and monolayers were rinsed 1×
with PBS. Each plate received 300 μl/well of SFM and the
plates again incubated using the conditions noted above.
For cytokine assays, culture supernatants were harvested
at time points between 12-48 h post gas vesicle applica-
tion, passed through a 0.2 μm syringe filter (Gelman
Sciences, Ann Arbor, MI) to remove any cell debris, and
then individually stored at - 20°C until assayed for cyto-
kines. For the gas vesicle degradation studies, coverslips
with monolayers were harvested at different times
between 12 and 120 h post application, rinsed 3× with
PBS, fixed using the cold 70% methanol (500 μl/well),
a n ds t o r e di ns e a l e dc u l t u r ep l a t e sa t-2 0 ° Cf o rs u b s e -
quent immunostaining as described below under intra-
cellular degradation.
Murine cytokine measurement by ELISA
Assays assessed three selected murine cytokines, poten-
tially present in the tissue culture media of murine
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at - 20°C as described above. Assessments used the fol-
lowing commercial kits: Mouse IL-18 ELISA Kit (#7625;
Medical & Biological Laboratories Co., Ltd. Naka-ku
Nagoya, Japan), Endogen® Mouse IL-12 ELISA Kit
EMIL12, and the Endogen® Mouse IL-10 ELISA Kit,
EMIL 10 (Pierce Biotechnology, Inc., Rockford, IL). The
IL-18 in vitro ELISA assay kit uses a sandwich format.
The two Endogen® kits are direct assays to measure the
quantity of biologically active mouse IL-12 (p70) and IL-
10 in culture supernatants, after it has bound to test
plates. Cytokine assay of the standards and experimental
samples were carried out in duplicate. Using the com-
puted average, ± standard deviation, standard curves
were generated and the average of duplicates for each
experimental sample used to determine picogram quan-
tities of each cytokine in each sample at each different
time point.
Briefly, the IL-18 ELISA Kit is a capture assay system
using wells that were commercially coated with an anti-
IL-18 monoclonal antibody. 100 μl of diluted IL-18 stan-
d a r d( 1 , 0 0 0 ,4 0 0 ,1 6 0 ,6 4 ,2 5 . 6a n d0p g / m l )o rs t e r i l e
culture supernatant in duplicate was incubated in the
wells for 1 h at RT, rinsed 4× with washing solution
provided in the kit. The IL-18 “captured” from the cul-
ture media then was detected with a second monoclonal
antibody pre-conjugated with horseradish peroxidase
(HRP). After incubation for 1 h at RT, wells were rinsed
4× with washing solution. Wells were filled with the
chromogen tetramethylbenzidine/hydrogen peroxide
(TMB), supplied with the kit and incubated 30 min at
R T .A na c i ds o l u t i o n( 0 . 5MH 2SO4) then was added to
each well to terminate the enzyme reaction and to stabi-
lize the developed color. The optical density (OD) of
each well is then measured at 450 nm using the Versa-
Max microplate reader. The concentrations of mouse
IL-18 were determined from the standard curve gener-
ated based on the absorbance of dilution series of the
IL-18 reference standard provided with the Kit. The
total concentration of mouse IL-18 for sample then is
determined by multiplying the value read from the stan-
dard curve by the dilution factor for the sample.
The Endogen® mouse IL-12 and IL-10 assay kits
included interleukin standards for cytokine quantifica-
tion and were used as specified by the manufacturer.
Prepared standards and samples were added to the anti-
Mouse IL-12 (p70) pre-coated wells in duplicate. The
plate was covered and incubated at RT for 2 h. Without
washing the plate, prepared biotinylated antibody
reagent was added to each well and incubated for 1 h.
After washing the plate 3× with wash buffer, ready to
use streptavidin-HRP solution was added and the plate
was incubated at RT for 30 minutes. Following another
washing, premixed TMB Substrate solution was added
and the plate was incubated in the dark for 30 minutes.
The reaction blocked by adding stop solution and the
absorbance measured on the plate reader at 450 nm.
The results were calculated using curve fitting statistical
software of the VersaMax instrument. For IL-10 detec-
tion, the procedures were similar with the following
exceptions: standards and sample were incubated for
3 h at RT and following this incubation, plates were
rinsed 3× with wash buffer before the biotinylated anti-
IL-10 antibody was added. As with the IL-12 kit, the
reaction was terminated with stop solution, the absor-
bance measured on the VersaMax plate reader at 450
nm and the results calculated using the VersaMax curve
fitting statistical software.
Intracellular degradation of gas vesicles
Assessment of phagocytosed gas vesicle intracellular fate
used the fixed, stored J774A.1 monolayers and applica-
tion of isolated, collapsed wild type or recombinant gas
vesicles described above in the cell culture methods.
Samples fixed at the 12, 24, 48, 72, 96 and 120 h post
gas vesicle application times were immunostained to
identify GvpC or the SIVsm derived moieties: Tat, Rev
and Nef1. After rinsing these monolayers with PBS, spe-
cific detection used either purified rabbit anti-GvpC
antibody (concentration 0.335 μg/μl) or plasma from an
SHIV-infected macaque (SHIV variant 89.6PD from ani-
mal number R94085; a gift from Dr. D. Pauza, Institute
of Human Virology, Baltimore, MD). These antibodies
were diluted 1:200 in PBS and 200 μl/well added to the
appropriate monolayers. Plates were then incubated at
37°C for 1 h. After rinsing 3× with PBS, cells were incu-
bated with a 1:50 dilution of FITC (fluorescein isothio-
cyanate) conjugated goat anti-rabbit secondary antibody
(Jackson Immuno Research, South Windham, ME) or
with FITC conjugated rabbit anti-monkey IgG (F3893;
S i g m aC h e m i c a lC o . ;S t .L o u i s ,M O ) .F o l l o w i n gi n c u b a -
tion at RT for 45 minutes, coverslips were rinsed with
PBS, then mounted on microscope slides using Vecta-
shield (H-1200; Vector Laboratories, Burlingame CA)
and sealed. Subsequently they were examined and digi-
tally documented using an Olympus BX41 microscope
and Olympus digital camera C-5050.
J774A.1 Cell lysate assessment by Western blot
Gas vesicle breakdown/intracellular protein degrada-
tion also was assessed by Western Blot. Briefly, mono-
layers of J774A.1 cells grown in 24 well plates were
then incubated with r-GV
Tat, Rev or Nef1 preparations,
or with wt-GV as described above. After removal of
the GV and addition of fresh media, cells were further
incubated for 48, 96 or 120 h. Cells were harvested
from the wells at those time points, lysed in a 5× SDS-
PAGE sample buffer (Pierce-Endrogen, Rockford, IL),
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of 20 μl were loaded into wells of a pre-cast 4-12%
NuPAGE® Novex Bis-Tris Gels (Invitrogen, Carlsbad,
CA) and following electrophoresis, usually 45-50 min,
the separated proteins were transferred to a PVDF
membrane (Millipore, Bedford, MA) using a BioRad
transfer apparatus (BioRad, Hercules, PA) following
the manufacturer’s instructions. SeeBlue PreStained
Standard (Invitrogen, Carlsbad, CA) was used to assess
the molecular weight of the proteins. Subsequently,
membranes were blocked with 5% non-fat dry milk
(NFDM) in PBS. This and all other incubations were
carried out at RT on a shaking platform. After block-
ing for 2.5 h, membranes were rinsed three times with
1% BSA/PBS. To identify the GvpC protein, half of
each blot was incubated with 0.020 μg/μlo fr a b b i t
anti-GvpC antibody diluted in 1% BSA/PBS. To iden-
tify SIVsm peptides expressed in the recombinant gas
vesicles, the other membrane half was incubated with
anti-SHIV macaque plasma described above, diluted
1:200 in 1% BSA/PBS. Following 1.5-2 h incubation
with appropriate anti-sera, membranes were rinsed
three times in 1% BSA/PBS. Specifically bound anti-
body was detected by incubating membranes with
either Alkaline Phosphatase (AP) conjugated goat anti-
rabbit IgG (H+L; Jackson Immuno Research, West
Grove, PA) or with alkaline phosphatase (AP) conju-
gated rabbit anti-monkey antibody (F3893; Sigma-
A l d r i c h ,S t .L o u i s ,M O ) .E a c hs e c o n d a r ya n t i b o d yc o n -
jugate was diluted 1:1,000 in 1% BSA/PBS and incuba-
tion continued for 1 h. Membranes were rinsed three
times with 1% BSA/PBS and twice with dH2O, and
then incubated with the alkaline phosphatase (AP)
membrane substrate, Sigma Fast (Sigma-Aldrich, St.
Louis MO); protein bands developed within 5 min of
substrate addition. Subsequently blots were rinsed in
distilled water; air dried at RT and archived as scanned
images.
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